A 52-year-old man with acute promyelocytic leukemia (APL) develops DIC after chemotherapy initiation. Which coagulation abnormality most reliably distinguishes APL-associated DIC from DIC secondary to sepsis?

Question

Accepted Answer

C. Severe hypofibrinogenemia with markedly elevated D-dimer and FDP. ## APL-Associated DIC vs. Sepsis-Associated DIC

### Pathophysiologic Basis

**Key Point:** APL-associated DIC is characterized by a **hyperfibrinolytic phenotype** driven by the release of procoagulant substances (tissue factor, cancer procoagulant) AND fibrinolytic activators (annexin II, tPA) from leukemic promyelocytes. This results in **severe hypofibrinogenemia with markedly elevated D-dimer and FDP** — the most reliable laboratory hallmark distinguishing APL-DIC from sepsis-DIC.

### Mechanism Comparison

| Feature | APL-DIC | Sepsis-DIC |
| --- | --- | --- |
| **Primary driver** | TF + Cancer Procoagulant + Annexin II (fibrinolysis) | Endotoxin → monocyte/endothelial TF expression |
| **Fibrinolysis** | ↑↑↑ (hyperfibrinolytic) | Variable (often suppressed by PAI-1) |
| **Fibrinogen** | ↓↓↓ (severely low, often <100 mg/dL) | ↓↓ (moderate reduction) |
| **D-dimer / FDP** | ↑↑↑ (markedly elevated) | ↑↑ (elevated, but less extreme) |
| **Platelets** | ↓↓↓ | ↓↓↓ |
| **PT / aPTT** | Prolonged | Prolonged |
| **Factor V** | Consumed (not reliably spared) | Consumed |

### Why Option A Is Correct

**High-Yield:** The hallmark of APL-DIC is **severe hypofibrinogenemia with markedly elevated D-dimer and FDP**, reflecting the dominant **hyperfibrinolytic** component. APL promyelocytes release:
1. **Annexin II** — overexpressed on APL cell surfaces, acting as a co-receptor for plasminogen and tPA, dramatically accelerating plasmin generation and fibrinolysis
2. **Tissue factor (TF) and cancer procoagulant (CP)** — driving thrombin generation and fibrin formation, which is then rapidly lysed

This combination of intense fibrin generation AND accelerated fibrinolysis produces **profoundly low fibrinogen** (often <50–100 mg/dL) and **extremely high D-dimer/FDP** — a degree of hypofibrinogenemia that is characteristically more severe than in typical sepsis-DIC, where PAI-1 elevation often suppresses fibrinolysis.

**Why Option B is incorrect:** While APL cells do express elevated TF and cancer procoagulant, the claim that Factor V is "normal or mildly reduced" in APL-DIC is **not supported by standard references** (Williams Hematology, Harrison's). Factor V is consumed in both APL-DIC and sepsis-DIC; Factor V preservation is not a reliable distinguishing feature in clinical practice.

**Clinical Pearl:** APL-DIC is treated with **ATRA + arsenic trioxide**, which differentiate APL cells, reducing release of procoagulant and fibrinolytic mediators. Cryoprecipitate and fresh frozen plasma are used to replace fibrinogen and clotting factors. Antifibrinolytics (e.g., tranexamic acid) are used cautiously given the thrombotic risk.

**Reference:** Levi M, Scully M. *How I treat disseminated intravascular coagulation.* Blood. 2018; Tallman MS, Altman JK. *How I treat acute promyelocytic leukemia.* Blood. 2009; Harrison's Principles of Internal Medicine, 21st ed., Chapter on Coagulation Disorders.

![DIC diagram](https://mmcphlazjonnzmdysowq.supabase.co/storage/v1/object/public/blog-images/explanation/2692.webp)

Answer

A. Thrombocytopenia with normal fibrinogen and low D-dimer

Answer

B. Isolated prolongation of PT with normal aPTT and normal platelet count

Answer

D. Elevated tissue factor (TF) and cancer procoagulant (CP) with normal or mildly reduced factor V

A 52-year-old man with acute promyelocytic leukemia (APL) develops DIC after chemotherapy initiation. Which coagulation abnormality most reliably distinguishes APL-associated DIC from DIC secondary to sepsis?

Explanation

APL-Associated DIC vs. Sepsis-Associated DIC

Pathophysiologic Basis

Mechanism Comparison

Why Option A Is Correct

Practice similar questions

Join our NEET PG community

Feature	APL-DIC	Sepsis-DIC
Primary driver	TF + Cancer Procoagulant + Annexin II (fibrinolysis)	Endotoxin → monocyte/endothelial TF expression
Fibrinolysis	↑↑↑ (hyperfibrinolytic)	Variable (often suppressed by PAI-1)
Fibrinogen	↓↓↓ (severely low, often <100 mg/dL)	↓↓ (moderate reduction)
D-dimer / FDP	↑↑↑ (markedly elevated)	↑↑ (elevated, but less extreme)
Platelets	↓↓↓	↓↓↓
PT / aPTT	Prolonged	Prolonged
Factor V	Consumed (not reliably spared)	Consumed